Rational use of medicines is essential for ensuring public health and preventing antimicrobial resistance. Discuss in the context of the regulation of Fixed Dose Combination (FDC)

Introduction

The rational use of medicines, as defined by the World Health Organization (WHO), requires that patients receive medicines appropriate to their clinical needs, in the correct doses, for an adequate duration, and at the lowest cost. In India, the widespread availability of Fixed Dose Combination (FDC) drugs—combinations of two or more active pharmaceutical ingredients in a single formulation—has improved treatment in many conditions. However, the proliferation of irrational FDCs, particularly involving antibiotics, has raised serious concerns regarding patient safety and antimicrobial resistance (AMR).

Significance of Rational Use of Medicines

1. Improves Therapeutic Outcomes

• Ensures appropriate drug selection, dosage, and duration of treatment.
• Minimises adverse drug reactions and medication errors.

2. Prevents Antimicrobial Resistance (AMR)

• Discourages unnecessary or inappropriate antibiotic use.
• Preserves the effectiveness of existing antimicrobials.

3. Reduces Healthcare Costs

• Prevents overmedication and irrational prescribing.
• Lowers expenditure arising from avoidable complications and treatment failures.

4. Enhances Patient Safety

• Reduces risks associated with drug interactions, toxicity, and polypharmacy.

Role of Fixed Dose Combination (FDC) Drugs

Benefits of Rational FDCs

1. Improved Patient Compliance

• Fewer tablets improve adherence, particularly in chronic diseases.

2. Better Clinical Outcomes

• Useful where combination therapy is scientifically justified.

Examples

• Tuberculosis
• HIV/AIDS
• Hypertension
• Diabetes

3. Reduced Pill Burden

• Simplifies treatment regimens and improves convenience.

Challenges Posed by Irrational FDCs

1. Inappropriate Antibiotic Use

• Irrational antibiotic combinations contribute to antimicrobial resistance.
• Patients may receive unnecessary broad-spectrum therapy.

2. Safety Concerns

• Increased risk of adverse drug reactions and harmful drug interactions.

3. Lack of Scientific Evidence

• Some FDCs are marketed without adequate evidence of efficacy or safety.

4. Diagnostic Difficulties

• Adverse effects become difficult to attribute to a specific drug component.

5. Regulatory Inconsistencies

• Historically, variations in approval processes between the Centre and States allowed irrational FDCs to enter the market.

Regulatory Framework in India

1. Drugs and Cosmetics Act, 1940

• Provides the legal framework for approval, manufacture, and sale of medicines.

2. Central Drugs Standard Control Organisation (CDSCO)

• Evaluates the safety, efficacy, and quality of new FDCs before approval.

3. Expert Committee Review

• Several irrational FDCs have been reviewed, and many have been prohibited following expert recommendations and judicial scrutiny.

4. National Action Plan on Antimicrobial Resistance (NAP-AMR)

• Promotes antimicrobial stewardship and rational prescribing.

Measures Required

1. Strengthen Scientific Evaluation

• Ensure that FDC approvals are based on robust clinical evidence of safety and efficacy.

2. Harmonise Regulatory Oversight

• Improve coordination between CDSCO and State Drug Regulatory Authorities.

3. Promote Antimicrobial Stewardship

• Develop hospital-based antibiotic stewardship programmes.
• Encourage adherence to Standard Treatment Guidelines (STGs).

4. Strengthen Pharmacovigilance

• Expand adverse drug reaction monitoring through the Pharmacovigilance Programme of India (PvPI).

5. Regulate Prescription Practices

• Enforce prescription-only sale of antibiotics and monitor irrational prescribing.

6. Public and Professional Awareness

• Educate healthcare professionals and patients on the rational use of medicines and the risks of AMR.

7. Encourage Evidence-Based Prescribing

• Promote continuous medical education and clinical decision-support systems.

Government Initiatives

• Central Drugs Standard Control Organisation (CDSCO)
• Pharmacovigilance Programme of India (PvPI)
• National Action Plan on Antimicrobial Resistance (NAP-AMR)
• National List of Essential Medicines (NLEM)

Value Addition

WHO AWaRe Classification: Categorises antibiotics into Access, Watch, and Reserve groups to promote responsible antibiotic use and reduce antimicrobial resistance.

Diagram

       Rational Use of Medicines
                  │
        Scientific Regulation
                  │
      Fixed Dose Combinations
                  │
 ┌───────────────┼────────────────┐
 │               │                │
Rational      Irrational      Regulation
FDCs          FDCs
 │               │                │
Better       AMR          CDSCO
Compliance   Adverse      PvPI
Outcomes     Effects      Evidence-Based Approval
 └───────────────┼────────────────┘
                  │
 Safe Medicines & Reduced AMR

Conclusion

Rational use of medicines is fundamental to improving health outcomes, protecting patient safety, and combating the growing threat of antimicrobial resistance. While scientifically validated Fixed Dose Combination drugs offer significant therapeutic advantages, irrational combinations undermine public health and increase antimicrobial resistance. A robust regulatory framework grounded in scientific evidence, effective pharmacovigilance, antimicrobial stewardship, and coordinated enforcement is essential to ensure that FDCs contribute to safe, effective, and affordable healthcare in India.

Value Addition (SDG Link): Strengthening the regulation and rational use of medicines advances SDG 3 (Good Health and Well-being) by promoting access to safe, effective, quality medicines and supporting global efforts to contain antimicrobial resistance.